Endocrine Abstracts

IntroductionRadioactive iodine (RAI) is a well-established treatment for relapsed Graves and toxic nodular hyperthyroidism. Lithium reduces the release of organic iodide and thyroid hormones from the thyroid gland, which results in a reduction of urinary radioiodine excretion. Previous studies have shown lithium may improve the effectiveness of radioiodine therapy; however research in this area is limited.Objective<p class="abs...

IntroductionPatients treated with radioiodine (RAI) for thyrotoxicosis, secondary to Graves or a toxic nodule, require close follow up to determine whether they have become hypothyroid or have a recurrence. National guidelines state that patients should have their first blood test at about six weeks post RAI. Telephoning patients with their results, rather than reviewing them at outpatient appointments, can be a more convenient and efficient method of fo...